Efficacy and Safety of Once-Weekly Semaglutide 2.0 mg as an Add-On to Dose-Reduced Insulin Glargine versus Dose-Titrated Insulin Glargine in People With Type 2 Diabetes and Overweight (SUSTAIN OPTIMIZE).

Diabetes Obes MetabJul 26, 2026 (epub)
Clinical ResearchEndocrinologyOpen access

Helena W Rodbard, Concetta Irace, Jevitha Lobo et al.

✦ AI-curated · Sources linked

In 30 seconds

The SUSTAIN OPTIMIZE trial evaluated the efficacy and safety of once-weekly semaglutide 2.0 mg as an add-on to dose-reduced insulin glargine versus dose-titrated insulin glargine in adults with type 2 diabetes and overweight. This 40-week randomized controlled trial found that semaglutide achieved superior reductions in HbA1c (ETD: -0.74%) and body weight (ETD: -8.5 kg) while reducing severe hypoglycaemia risk.

Key findings

  • Semaglutide reduced HbA1c by -0.74% compared to dose-titrated insulin glargine.
  • Participants lost an average of 8.5 kg with semaglutide versus insulin glargine.
  • Daily insulin dose decreased by 121.9% with semaglutide compared to insulin glargine.
  • Severe hypoglycaemia rates were reduced with semaglutide (rate ratio: 0.45).

Why it matters

This study highlights the potential of semaglutide as an effective adjunct therapy for managing type 2 diabetes in overweight patients, addressing both glycaemic control and weight management while minimizing the risk of severe hypoglycaemia.

Source

PubMed · PMID 42504064Free full text on PubMed Central

Published in Diabetes Obes Metab. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.